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Abstract
Background: Elevated pulmonary vascular resistance (PVR) is common following 
repair of truncus arteriosus. Inhaled nitric oxide (iNO) is an effective yet costly 
therapy that is frequently implemented postoperatively to manage elevated PVR.
Objectives: We aimed to describe practice patterns of iNO use in a multicenter 
cohort of patients who underwent repair of truncus arteriosus, a lesion in which 
recovery is often complicated by elevated PVR. We also sought to identify patient 
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1  | INTRODUC TION
Recovery from surgery for congenital heart disease is frequently 
complicated by elevated pulmonary vascular resistance (PVR), which 
can cause clinical decompensation secondary to pulmonary hyper-
tension and right ventricular failure. Inhaled nitric oxide (iNO) is 
an effective but expensive therapy commonly implemented in this 
clinical scenario.1-3 iNO acts as a selective pulmonary vasodilator by 
activating soluble guanylate cyclase converting guanosine triphos-
phate into cyclic guanosine monophosphate. This cascade decreases 
pulmonary vascular tone without adverse systemic effects. iNO is 
an effective treatment for potentially life‐threatening exacerbations 
of pulmonary hypertension in the period following cardiopulmonary 
bypass.4-6 It can also be used prophylactically, in hopes of prevent-
ing the undesirable hemodynamic effects of elevated PVR such 
as low cardiac output secondary to right ventricular dysfunction.4 
Pulmonary hypertension has been associated with longer duration 
of mechanical ventilation, prolonged ICU stay, hospital stay, and 
mortality for children undergoing surgery for congenital heart dis-
ease. Mitigation of pulmonary hypertension is therefore an import-
ant postoperative goal.7,8
Truncus arteriosus is a complex congenital cardiac anomaly, 
first described by Wilson in 1798,9 wherein the pulmonary arteries 
fail to separate from the aorta in utero resulting in a common ar-
terial trunk. A large left‐to‐right shunt often results from this anat-
omy, preventing PVR from decreasing during the neonatal period 
and thus predisposing these children to postoperative pulmonary 
hypertension. This lesion is typically repaired surgically shortly 
after birth,10,11 with many children receiving iNO postopera-
tively.12-14 The indications for iNO use after repair of truncus ar-
teriosus and other congenital heart surgeries are not well defined. 
We therefore sought to examine the use of iNO following surgi-
cal repair of truncus arteriosus, a relatively homogenous group of 
patients across institutions, to provide insight into contemporary 
practice patterns surrounding this effective but expensive ther-
apy. We also aimed to identify whether any specific patient or cen-
ter factors were more likely to be associated with iNO use in the 
postoperative period.
2  | MATERIAL S AND METHODS
2.1 | Study population
We performed secondary analysis of data collected by retrospective 
review of infants who underwent primary surgical repair of truncus 
arteriosus between 2009 and 2016 at 15 tertiary care centers within 
and center factors that were more commonly associated with the use of iNO in the 
postoperative period.
Design: Retrospective cohort study.
Setting: 15 tertiary care pediatric referral centers.
Patients: All infants who underwent definitive repair of truncus arteriosus without 
aortic arch obstruction between 2009 and 2016.
Interventions: Descriptive statistics were used to demonstrate practice patterns of 
iNO use. Bivariate comparisons of characteristics of patients who did and did not re-
ceive iNO were performed, followed by multivariable mixed logistic regression analy-
sis using backward elimination to identify independent predictors of iNO use.
Main Results: We reviewed 216 patients who met inclusion criteria, of which 102 
(46%) received iNO in the postoperative period: 69 (68%) had iNO started in the op-
erating room and 33 (32%) had iNO initiated in the ICU. Median duration of iNO use 
was 4 days (range: 1‐21 days). In multivariable mixed logistic regression analysis, use 
of deep hypothermic circulatory arrest (odds ratio: 3.2; 95% confidence interval: 1.2, 
8.4) and center (analyzed as a random effect, p = .02) were independently associated 
with iNO use.
Conclusions: In this contemporary multicenter study, nearly half of patients who un-
derwent repair of truncus arteriosus received iNO postoperatively. Use of iNO was 
more dependent on individual center practice rather than patient characteristics. The 
study suggests a need for collaborative quality initiatives to determine optimal crite-
ria for utilization of this important but expensive therapy.
K E Y W O R D S
circulatory arrest, congenital, deep hypothermia induced, heart defects, multicenter study, 
nitric oxide, postoperative period, truncus arteriosus
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the United States. The study was approved by the institutional re-
view boards at all participating centers and the need for informed 
consent was waived given the retrospective nature of data collec-
tion. A list of participating institutions is provided in Supplemental 
Table 1. The following patients were excluded from analysis: (1) 
children who underwent pulmonary artery banding but died prior to 
definitive repair; (2) children with hemitruncus (ie, right pulmonary 
artery arising from the aorta) or pseudotruncus (ie, pulmonary atre-
sia with major aortopulmonary collaterals); and (3) children who un-
derwent concomitant repair of truncus arteriosus with IAA or aortic 
arch obstruction (Van Praagh Type A4).
2.2 | Data collection and definitions
Preoperative, intraoperative, and postoperative data were collected 
for all patients. Center volume was defined by average cases per 
year during the study period and categorized as follows:
• Category I: ≤1 case per year
• Category II: >1 ≤2 cases per year
• Category III: >2 ≤3 cases per year
• Category IV: >3 cases per year
Center characteristics also included data collected via a survey of 
participating centers on unit composition (mixed cardiac and general 
ICU population vs dedicated CICU) and physician training (primar-
ily ICU‐trained, primarily cardiology‐trained or dual‐trained in both 
cardiology and intensive care). Preoperative ventilation was defined 
as mechanical ventilation within 24 hours of surgery. Preoperative 
inotropic support was defined as use of any inotropic infusion within 
24 hours of cardiac surgery. Preoperative shock was defined as 
pH less than 7.2 or lactate greater than 4 mg/dL per the Society of 
Thoracic Surgeons Congenital Heart Surgery Database (STS‐CHSD) 
definition.15 Extubation failure was defined as intubation within 72 
hours of initial extubation attempt. Operative mortality was defined 
as mortality occurring before hospital discharge, within 30 days or 
the index cardiac operation, or in a secondary chronic care facility (or 
rehabilitation facility) within 180 days following index cardiac opera-
tions per STS‐CHSD definition.
2.3 | Statistical analysis
Data including patterns of iNO use are represented using descriptive 
statistics. Medians with 25th and 75th percentiles for continuous 
variables and absolute counts with percentages for categorical varia-
bles were employed unless otherwise noted. Bivariate analyses were 
performed comparing characteristics of patients who received iNO 
therapy to patients who did not using Wilcoxon sum rank tests and 
Chi‐squared tests. All variables with P values < .2 on bivariate analy-
ses were considered for inclusion in a multivariate logistic regression 
model. Linearity in the logit was examined for continuous variables 
prior to model building; variables with evidence of nonlinearity were 
converted to categorical variables. Multivariable logistic regression 
analysis was performed using stepwise selection to identify inde-
pendent predictors of iNO use. The multivariable logistical model 
was then analyzed as a mixed model including center as a random ef-
fect. Results of the multivariable analysis are reported as odds ratio 
(OR) with 95% confidence intervals (CI). All statistical analyses were 
performed using STATA version 14 and SAS version 9.4.
3  | RESULTS
We identified and reviewed 216 patients with truncus arteriosus 
who met the inclusion criteria. During the study period, 102 (46%) 
received iNO therapy in the postoperative period, 69 (68%) of whom 
had iNO started in the operating room, and 33 (32%) of whom had 
iNO initiated in the ICU following surgery. Median duration of iNO 
use was 4 days (range: 1‐21) and median maximum dose was 20 ppm 
(range: 10‐40). The proportion of patients who received iNO ther-
apy did not change significantly over the duration of study period 
(Figure 1). The relationship between center and iNO use is illustrated 
in Figure 2. There was significant variation in iNO use across cent-
ers. Additionally, for patients who received iNO, the location where 
iNO was initiated varied significantly across centers, such that initia-
tion of iNO in the OR was the dominant practice at some centers 
while initiation of iNO more commonly occurred in the ICU at other 
centers.
The relationship of center characteristics and iNO use is sum-
marized in Table 1. There was a significant association between 
center volume and iNO use, with the highest volume centers less 
likely to implement this therapy, P < .001. Use of iNO was also more 
frequently implemented in centers with multidisciplinary pediatric 
ICUs (as compared to dedicated cardiac ICUs) and centers at which 
attending physicians had predominantly ICU training (as compared 
to centers at which attending physicians had predominantly cardiol-
ogy training). Centers where the majority of intensivists were dual‐
trained had the highest proportion of patients who received iNO, 
though 23 of the 26 patients at these centers who received iNO had 
the therapy initiated in the OR rather than in the ICU.
Comparisons of baseline or preoperative characteristics of pa-
tients who did and did not receive iNO after their definitive trun-
cus arteriosus repair are listed in Table 2. On bivariate analysis, 
iNO patients tended to be older at the time of their first opera-
tion (ie, definitive repair in 213 patients, pulmonary artery banding 
followed by definitive repair in three patients) and the time from 
diagnosis to the first operation was significantly longer in patients 
who received iNO. Patients who received iNO were also signifi-
cantly more likely to be prescribed furosemide preoperatively and 
have diminished left ventricular function on preoperative echo-
cardiogram. Bivariate comparison of operative variables is pro-
vided in Table 3. From this analysis, duration of cardiopulmonary 
bypass as well as use of modified ultrafiltration, deep hypother-
mic circulatory arrest (DHCA), and intraoperative corticosteroids 
were significantly more common in patients who received iNO 
postoperatively.
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Results of our multivariable analysis are shown in Table 4. In a 
model unadjusted for center, use of intraoperative corticosteroids, 
use of modified ultrafiltration, use of deep hypothermic circulatory 
arrest, and depressed left ventricular function prior to surgery were 
identified as independent risk factors for use of iNO postoperatively. 
Duration of cardiopulmonary bypass, though not statistically signif-
icant, was deemed to have an appreciable effect on the model and 
therefore also included. When center was added to the model, only 
use of DHCA (OR: 3.2, 95% CI: 1.2, 8.4, P = .018) and center (P = .02) 
was independently associated with iNO.
F I G U R E  1   Use of iNO over time 
among patients who underwent truncus 
arteriosus repair between 2009 and 
2016. The proportion of patients who 
received iNO (white) as compared to the 
proportion of patients who did not receive 
iNO (black) after surgical repair did not 
vary significantly over time (p = .44)
F I G U R E  2   Variation in iNO use after 
definitive repair of truncus arteriosus 
across centers (2009‐2016). Patients who 
received iNO initiated in the OR (black), 
patients who received iNO initiated in the 
ICU, and patients who did not receive iNO 
(white) are provided for each of the 15 
participating centers. The proportion of 
patients who received iNO (P < .001) and 
the location where iNO was initiated (P < 
.001) varied significantly across centers
Variable All patients (N = 216) No iNO (n = 114) iNO (n = 102) P value
Postoperative ICU care model <.001
Dedicated CICU (n = 10) 194 (90%) 110 (96%) 84 (82%)  
Multidisciplinary ICU (n = 5) 22 (10%) 4 (4%) 18 (18%)  
Predominant training pathway of ICU attending physicians .017
ICU training (n = 11) 128 (59%) 68 (60%) 60 (58%)  
Cardiology training (n = 2) 53 (25%) 37 (32%) 16 (16%)  
ICU + Cardiology training 
(n = 2)
35 (16%) 9 (8%) 26 (25%)  
Center volume <.001
≤1 surgery/year (n = 5) 18 (8%) 7 (6%) 11 (11%)  
 (1‐2] surgeries/year (n = 2) 26 (12%) 10 (9%) 16 (16%)  
 (2‐3] surgeries/year (n = 6) 112 (52%) 45 (40%) 67 (66%)  
>3 surgeries/year (n = 2) 60 (28%) 52 (46%) 8 (8%)  
TA B L E  1   Center characteristics for 
patients who did and did not receive 
iNO after repair of truncus arteriosus 
(2009‐2016)
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Postoperative characteristics and clinical outcomes for patients 
who did and did not receive iNO are provided in Table 5. Disease 
acuity was higher in patients who received iNO; significantly greater 
VVR scores 12 hours postoperatively, more frequent use of ECMO 
or CPR, and significantly longer durations of mechanical ventilation 
and hospital stay were observed in this cohort.
We also performed a subanalysis comparing all variables listed in 
Tables 1‐3 and outcomes listed in Table 5 from patients in which iNO 
was initiated in the OR and patients in which iNO was initated in the 
ICU. Select variables from this bivariate comparison are provided in 
Table 6 (supplemental online only). A significantly greater proportion 
of patients had iNO initiated in the OR at centers with dedicated 
cardiac ICUs and at centers in which the attending physicians car-
ing for these patients were predominantly ICU trained, while there 
was no significant difference in center volume (data not shown), ex-
posure to DHCA, or any postoperative outcomes between the two 
subgroups.
4  | DISCUSSION
In our analysis of a multicenter cohort of children who underwent 
repair of truncus arteriosus, we found the utilization of iNO to be 
fairly common, with nearly half of patients included receiving iNO in 
TA B L E  2   Preoperative characteristics for patients who did and did not receive iNO therapy after repair of truncus arteriosus (2009‐2016)
Variablea All patients (N = 216) No iNO (n = 114) iNO (n = 102) P value
Prenatal diagnosis 135 (63%) 72 (63%) 63 (62%) .83
Age at diagnosis (days) 0 (0, 2) 0.0 (0, 2) 0 (0, 1) .64
Truncus type .20
Van Praagh 1A 112 (52%) 65 (57%) 47 (46%)  
Van Praagh 1B 90 (42%) 41 (36%) 49 (48%)  
Van Praagh 1C 14 (6%) 8 (7%) 6 (6%)  
Female sex 108 (50%) 56 (49%) 52 (51%) .79
Race .13
Caucasian 147 (68%) 84 (74%) 63 (62%)  
African American 33 (15%) 16 (14%) 17 (17%)  
Other/Unknown 36 (18%) 14 (12%) 22 (22%)  
Prematurity (<37 weeks) 42 (19%) 21 (18%) 21 (21%) .69
Diagnosis before discharge 171 (79%) 90 (79%) 81 (79%) .93
Chromosomal anomaly, any 83 (38%) 49 (43%) 34 (33%) .15
DiGeorge/22q.11 deletionb 61 (28%) 36 (32%) 25 (25%) .25
Non‐cardiac abnormalities 63 (29%) 29 (25%) 34 (33%) .20
Preoperative shock 21 (10%) 9 (8%) 12 (12%) .34
Preoperative ventilationc 45 (21%) 22 (19%) 23 (23%) .56
Preoperative furosemide 146 (68%) 70 (61%) 76 (75%) .04
Preoperative inotropic supportc 28 (13%) 15 (13%) 13 (13%) .93
Age at first operation (days)d 10 (7, 23) 8.5 (6, 16) 11.5 (7, 27) .06
Diagnosis to first operation (days) 8 (5.5, 15) 7 (5, 13) 9 (6, 20) .04
Decreased LV function 24 (11%) 7 (6%) 17 (17%) .01
Decreased RV function 33 (15%) 12 (11%) 21 (21%) .04
Decreased BV function 20 (9%) 6 (5%) 14 (14%) .03
Valve insufficiency .34
Mild 51 (24%) 26 (23%) 25 (25%)  
Mild‐moderate 14 (6%) 6 (5%) 8 (8%)  
Moderate 35 (16%) 16 (14%) 19 (19%)  
Moderate‐severe 9 (4%) 5 (4%) 4 (4%)  
Severe 8 (4%) 2 (2%) 6 (6%)  
aContinuous variables presented as median (25%, 75%), categorical data presented as counts (%). 
b207 of 216 patients were tested for DiGeorge syndrome/22q.11 deletion. 
cWithin 24 hours of cardiac surgery. 
dThree patients received pulmonary artery banding as a first operation prior to subsequent definitive repair. 
     |  1083RILEY Et aL.
Variablea All patients (N = 216) No iNO (n = 114) iNO (n = 102) P value
CPB duration (min) 150 (124, 186) 143 (118, 179) 158 (130, 203) .008
CPB less than 150 min 108 (50%) 65 (57%) 43 (42%) .03
Cross‐clamp duration (min) 86 (73, 111) 90 (70, 111) 85 (74, 111) .56
DHCA (n) 31 (14%) 10 (9%) 21 (21%) .01
Lowest temperature (°C) 25.0 (21.4, 28.0) 25.4 (22.0, 28.0) 25 (20.0, 28.0) .06
MUF use 139 (64%) 61 (54%) 78 (77%) <.001
Intraoperative 
corticosteroids
161 (75%) 76 (67%) 85 (83%) .005
RV‐PA conduit size (mm) 11 (9, 12) 11 (9, 12) 11 (9, 12) .97
RV‐PA conduit size (mm/
m2)
51 (46, 56) 51 (46, 57) 51(45, 56) .49
Truncal valve surgery 37 (17%) 19 (17%) 18 (18%) .85
Factor VIIa 34 (16%) 16 (14%) 18 (18%) .47
Abbreviations: CPB, cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; MUF, 
modified ultrafiltration; RV‐PA, right ventricle‐to‐pulmonary artery.
aContinuous variables presented as median (25%, 75%), categorical variables presented as counts (%). 
TA B L E  3   Comparison of operative 
characteristics of patients who did and 
did not receive iNO therapy after repair of 
truncus arteriosus (2009‐2016)
Variable Odds ratio 95% confidence interval P value
Unadjusted model
Modified ultrafiltration 3.8 2.0-7.2 <.001
Intraoperative corticosteroids 4.0 1.9-8.4 <.001
Depressed left ventricular function 4.4 1.5-13.0 .008
Deep hypothermic circulatory arrest 2.9 1.2-7.2 .017
Cardiopulmonary bypass > 150 min 1.8 1.0-3.2 .067
Model adjusted for center
Deep hypothermic circulatory arrest 2.9 1.1-7.5 .034
Centera   .02
aAnalyzed in the model as a random effect; odds ratios for individual centers were not calculated. 
TA B L E  4   Multivariable mixed logistic 
regression analysis for predictors of iNO 
use after repair of truncus arteriosus
Variablea All patients (N = 216) No iNO (n = 114) iNO (n = 102) P value
Delayed sternal closure 126 (58%) 64 (56%) 62 (61%) .49
ECMO 22 (10%) 6 (5%) 16 (6%) .01
CPR 26 (12%) 8 (7%) 18 (18%) .02
Reoperation for bleeding 19 (9%) 7 (6%) 12 (12%) .15
Reoperation not for 
bleeding
25 (12%) 9 (8%) 16 (16%) .07
VVR at 12 hb 30 (23, 42) 28 (21, 37) 34 (25, 45) <.001
Mechanical ventilation (h) 140 (86, 264) 108 (72, 168) 193 (116, 532) <.001
Extubation failure 22 (10%) 9 (8%) 13 (13%) .24
Hospital LOS (days) 23 (15, 43) 20 (13, 33) 28 (18, 51) <.001
Operative mortality 15 (7%) 5 (4%) 10 (10%) .12
Abbreviations: CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygena-
tion; LOS, length‐of‐stay.
aContinuous variables presented as median (25%, 75%), categorical variables presented as counts (%). 
bVasoactive‐ventilation‐renal score = vasoactive‐inotrope score + ventilation index + Δ creatinine 
[change in serum creatinine from baseline*10], not calculated for 17 patients on ECMO at 12 hours. 
TA B L E  5   Comparison of clinical 
outcomes of patients who did and did 
not receive iNO therapy after repair of 
truncus arteriosus (2009‐2016)
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the postoperative period. While the percentage of patients who re-
ceived iNO postoperatively remained relatively consistent over time, 
we noted considerable variation in iNO practice patterns across 
centers and determined center to be independently associated with 
postoperative iNO therapy. We assume that some of the patients 
who received iNO likely did so in response to clinical evidence of 
potentially life‐threatening right ventricular hypertension, but the 
observed variability in usage across centers, with some centers ini-
tiating iNO in all or most of their patients and other centers utiliz-
ing the therapy in few or none of their patients, suggests that iNO 
utilization in some patients may not have been necessary but rather 
driven by center practice.
We did identify associations between some center charac-
teristics and iNO utilization. For example, lower volume centers 
tended to use iNO more frequently, a finding that was also noted 
in a prior study examining use of iNO in cardiac centers partici-
pating in the Pediatric Health Information System database.16 We 
also noted an increase in iNO use in centers without dedicated 
cardiac ICUs or centers where patients were managed by physi-
cians with critical care training. While it is possible that providers, 
either in the OR and in the ICU, who less commonly encounter 
children with this complex lesion may have lower thresholds to 
start iNO as a precautionary measure, or that iNO use could be in-
fluenced by ICU care model or physician training, we cannot make 
definitive conclusions about these relationships based on the lim-
ited number of centers in each of the designated categories. It 
must also be noted that there are undoubtedly intangible factors 
that influenced providers’ decision whether or not to initiate iNO 
that could not be measured in this study, some of which are likely 
to be center‐specific.
Variability of iNO usage is not unique to patients with congenital 
heart disease. Other studies have found similar patterns of variability 
in other patient populations including premature infants and infants 
following congenital diaphragmatic hernia repair.17,18 Moreover, in 
a study of neonates with persistent pulmonary hypertension, an 
effort to protocolize initiation and weaning of iNO was shown to 
be successful in decreasing utilization and, accordingly, the costs as-
sociated with this therapy.19 To our knowledge, however, effective 
protocols identifying clinical triggers for initiation and weaning of 
iNO following pediatric cardiac surgery are generally lacking in the 
literature. Simsic and coworkers described their attempt to decrease 
iNO usage and minimize practice variation using an initiation proto-
col for pediatric patients with cardiac disease.20 This study found 
that while variation among providers was reduced, usage rates and 
associated costs did not change, even with generally high compli-
ance to the protocol. In another single center study by Tzanetos et 
al, the authors were able to demonstrate a decrease in direct costs 
associated with iNO use following implementation of an iNO initia-
tion and weaning protocol in a mixed cardiac and general pediatric 
intensive care unit, though protocol adherence did not correlate with 
the decrease in cost.21 In these studies, protocols were aimed at re-
ducing variation across providers within a single institution.
Given the marked variation in iNO use across centers observed 
in our study, multicenter collaboration to create protocols aimed 
at reducing variation in iNO use across institutions could be more 
illuminating and should be pursued. In particular, collaboration be-
tween centers with very low and very high iNO utilization rates 
could identify potential pathways for decreasing iNO use at the 
TA B L E  6   Comparison of characteristics and outcomes of 
patients who had inhaled nitric oxide (iNO) initiated in the 
operating room (OR) versus the ICU
Variable
iNO in OR 
(n = 69)
iNO in ICU 
(n = 33) P value
Prenatal diagnosis 38 (55%) 25 (76%) .04
Truncus type .04
Van Praagh 1A 26 (38%) 21 (64%)  
Van Praagh 1B 39 (57%) 10 (30%)  
Van Praagh 1C 4 (6%) 2 6%)  
No diagnosis before 
nursery discharge
16 (23%) 5 (15%) .44
Age at first operation 
(days)
11 (7, 30) 12 (8, 20) .81
Preoperative decreased 
RV function
14 (20%) 5 (15%) .60
≥ moderate preopera-
tive valve insufficiency










16 (23%) 5 (15%) .35
Lowest temperature (°C) 24 (20, 28) 25 (24, 28) .22
Modified ultrafiltration 
use
56 (81%) 22 (67%) .10
Intraoperative 
corticosteroids
61 (88%) 24 (72%) .047
Concomitant truncal 
valve surgery
10 (14%) 8 (24%) .23
Recovered in dedicated 
cardiac ICU
61 (88%) 23 (70%) .02
Training pathway of ICU physicians .02
ICU 35 (51%) 25 (76%)  
Cardiology 11 (16%) 5 (15%)  
ICU + Cardiology 23 (33%) 3 (9%)  
Delayed sternal closure 44 (64%) 18 (55%) .37
Postoperative ECMO 11 (16%) 5 (15%) 1.00











Hospital LOS (days) 30 (15, 51) 25 (18, 49) .99
Operative mortality 6 (9%) 4 (12%) .73
Continuous variables represented as median (25%, 75%), categorical 
data represented as counts (%).
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latter institutions. Further, protocols containing physiologic trig-
gers for initiation, whether it be in the operating room or ICU, with 
goal‐driven maintenance algorithms are reasonable starting points. 
Resource utilization and associated costs of caring for children with 
congenital heart disease remain high. Using data from the Pediatric 
Health Information System database, Smith and colleagues found 
preoperative and postoperative management charges for patients 
undergoing congenital heart surgery in 2011 to be approximately 
$433 875 per case.22 The authors also found that mean duration of 
iNO use escalated from 2005 to 2011 (ie, 5.3 days to 6.6 days) and 
represented more than $50 000 of the average charges per patient 
exposed. Thus, as healthcare costs continue to rise, protocols to 
guide iNO usage may represent an opportunity for resource conser-
vation and cost containment. To reduce the marked variation of iNO 
use we observed, utilization of a multicenter quality improvement 
collaborative to create and implement a standardized protocol for 
iNO initiation, including assessment of patient response to therapy 
and deliberate weaning if no objective evidence of clinical benefit 
are apparent, would be a reasonable next step.
In addition to center, we identified DHCA to be an independent 
predictor of iNO usage. From our data, however, we are unable to 
definitively discern whether the latter finding reflects a physiolog-
ical relationship between DHCA and elevated PVR leading to the 
use of iNO to mitigate pulmonary hypertension or right ventricular 
dysfunction, or a heightened perception of patient acuity by provid-
ers in the setting of DHCA prompting prophylactic iNO use. DHCA 
could prolong the necessity for cardiopulmonary bypass due to re-
warming, and this prolonged exposure to cardiopulmonary bypass 
could result in more exaggerated elevations in PVR postoperatively. 
In a seminal report by Wernovsky et al, elevated PVR was observed 
in patients who underwent the arterial switch operation with DHCA 
or low‐flow cardiopulmonary bypass.23 Additionally, in a porcine 
model of hypothermic circulatory arrest, Cooper and colleagues 
demonstrated impaired endothelial vasorelaxation in cerebral arter-
ies, renal arteries, and pulmonary veins.24 Based on these data and 
the center‐independent association between DHCA and iNO use, it 
is plausible that the observed relationship between DHCA and iNO 
use was related to pathologic increase in PVR. Exposure to DHCA 
may therefore be an appropriate clinical trigger for iNO usage after 
surgery for congenital heart disease.
This study has several limitations. The retrospective nature of 
the study affected our ability to include a more exhaustive list of 
clinically relevant variables in our analyses. Most notably, specific 
clinical or echocardiography findings commonly associated with ele-
vated PVR (eg, direct measurements of pulmonary artery pressures; 
tricuspid valve regurgitation jet velocity) were not routinely captured 
by most centers, preventing us from being able to assess the clinical 
decision‐making process behind initiation of iNO. The sparsity of 
this information in the medical record, however, suggests that the 
decision to start iNO in many cases was likely not based on objective 
data but rather was prophylactic or based on subjective concerns for 
right ventricular hypertension. Other treatment strategies that may 
have mitigated the presence or severity of pulmonary hypertension, 
such as acid‐base management, use of other pulmonary vasodilatory 
therapies, or the use of pharmacologic paralysis, were not assessed. 
The study was also not designed to determine if iNO usage had a 
significant effect on patient outcomes. The associations identified 
between iNO use and worse clinical outcomes should therefore not 
be interpreted as causal. Based on the marked variation in iNO use 
across centers, however, a study that randomizes patients with mod-
erate postoperative disease severity to empirically receive or not re-
ceive iNO therapy could be possible and should be pursued.
5  | CONCLUSIONS
In a contemporary multicenter dataset, nearly half of patients with 
truncus arteriosus who underwent repair received iNO, and usage 
did not vary significantly over time. We identified DHCA as an inde-
pendent risk factor for iNO use and observed a strong relationship 
between center and iNO use while adjusting for patient characteris-
tics suggesting center practice as an important predictor of iNO use. 
These findings indicate a need for multicenter collaborative quality 
improvement initiatives to determine best practices for this impor-
tant but expensive therapy.
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